Showing results (351-360 of 395) with videos related to
Sort By:
Pageof 40
British Journal of Cancer|April 20, 2016
Adjuvant ovarian function suppression and cognitive function in women with breast cancerKelly-Anne Phillips, Meredith M Regan, Karin Ribi, et al.The Lancet. Oncology|January 21, 2014
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trialStefan Aebi, Shari Gelber, Stewart J Anderson, et al.Breast Cancer Research and Treatment|October 24, 2015
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trialsMeredith M Regan, Olivia Pagani, Prudence A Francis, et al.Breast Cancer Research and Treatment|April 11, 2020
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapyKarin Ribi, Weixiu Luo, Barbara A Walley, et al.The Lancet. Oncology|March 1, 2011
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trialLuca Gianni, Urania Dafni, Richard D Gelber, et al.European Journal of Cancer (Oxford, England : 1990)|August 5, 2019
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancerJens Huober, Eileen Holmes, José Baselga, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2017
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy TrialsPoornima Saha, Meredith M Regan, Olivia Pagani, et al.The Lancet. Oncology|March 16, 2013
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trialViviana Galimberti, Bernard F Cole, Stefano Zurrida, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2021
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-UpMartine Piccart, Marion Procter, Debora Fumagalli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2016
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function TrialKarin Ribi, Weixiu Luo, Jürg Bernhard, et al.Pageof 40